Literature DB >> 30227411

Brief Report on 3-Weekly Paclitaxel Carboplatin Efficacy in Locally Advanced or Metastatic Squamous Vulvar Cancer.

Frédéric Amant1,2,3, Linda Nooij4, Daniela Annibali5,6, Anne-Sophie van Rompuy7, Sileny Han6, Heidi van den Bulck8,9, Frédéric Goffin10.   

Abstract

In this brief report, we present our experience with 3-weekly paclitaxel-carboplatin chemotherapy for patients with vulvar cancer. Two patients with locally advanced disease had an impressive response allowing standard vulvar cancer surgery. One patient with metastatic disease had local stable disease though it was progressive in the lymph nodes. The available literature is sparse and retrospective. Based on promising results, however, a prospective multicenter study is mandatory in order to obtain full data in a larger series of patients in order to learn the benefits of neoadjuvant paclitaxel-carboplatin and compare the results with chemoradiation.
© 2018 S. Karger AG, Basel.

Entities:  

Keywords:  Advanced vulvar cancer; Chemoradiation; Neoadjuvant chemotherapy; Treatment

Mesh:

Substances:

Year:  2018        PMID: 30227411     DOI: 10.1159/000487435

Source DB:  PubMed          Journal:  Gynecol Obstet Invest        ISSN: 0378-7346            Impact factor:   2.031


  3 in total

Review 1.  Management of Advanced Squamous Cell Carcinoma of the Vulva.

Authors:  Linda J Rogers
Journal:  Cancers (Basel)       Date:  2021-12-30       Impact factor: 6.639

2.  Cancer of the vulva: 2021 update.

Authors:  Alexander B Olawaiye; Mauricio A Cuello; Linda J Rogers
Journal:  Int J Gynaecol Obstet       Date:  2021-10       Impact factor: 4.447

3.  Recommendations for the treatment of vulvar cancer in settings with limited resources: Report from the International Gynecological Cancer Society consensus meeting.

Authors:  Fernando Cotait Maluf; Graziela Dal Molin Zibetti; Eduardo Paulino; Andreia Cristina de Melo; Douglas Racy; Robson Ferrigno; Pedro Luiz Serrano Uson Junior; Reitan Ribeiro; Renato Moretti; Jose Carlos Sadalla; Angelica Nogueira Rodrigues; Filomena Marino Carvalho; Glauco Baiocchi; Donato Callegaro-Filho; Roberto Angioli
Journal:  Front Oncol       Date:  2022-09-20       Impact factor: 5.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.